drugset / Trial / NCT02603068

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

NCT02603068

Phase 2 Withdrawn United Therapeutics
RandomizedParallel-groupOpen-labelTreatment

Summary

This multicenter, randomized, open-label study will assess the safety and efficacy of oral treprostinil in subjects diagnosed with pulmonary hypertension associated with pulmonary fibrosis.

Timeline

Start
2016-02
Primary completion
2018-04
Completion
2018-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Treprostinil Other / unclassified 1 mg Oral
Subject Treprostinil Other / unclassified 12 mg Oral